Sign in
Not yet taking people in SpainPhase 4

Studying how an SGLT2 inhibitor works in heart failure with preserved ejection fraction

Tests how an SGLT2 inhibitor acts in adults with heart failure with preserved ejection fraction.

Key facts

Who runs it
Fundación para la Innovación en Biomedicina
Where
Madrid, SpainSee the site
Registry title
Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction
Status
Not yet recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
1 Jun 2023
Planned end
1 Jun 2026
Type of study
Interventional
Record updated
31 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure with preserved ejection fraction (LVEF 50% or more) who are clinically stable and are about to start an SGLT2 inhibitor medicine for the first time.

Age
18 years or older
Sex
All sexes
Disease stage
Heart failure with LVEF ≥ 50% and signs of diastolic dysfunction on heart ultrasound. A hospital stay or intravenous diuretic treatment in the previous 6 months. Stable for more than 1 month. People with or without type 2 diabetes can join.
Earlier treatment
Must not have had SGLT2 inhibitor treatment before or now. Must have a clinical indication to start a new SGLT2 inhibitor. Must have a clinical indication for cardiac catheterization.

Main reasons for not taking part

  • Taking part in another clinical trial in the last 30 days
  • Pregnant or breastfeeding women
  • Significant coronary artery disease
  • Aortic or mitral valve disease of moderate degree or worse
  • Stroke in the last 12 months

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adults of both genders ≥ 18 years
  • LVEF ≥ 50%
  • Diagnosis of HFpEF according to clinical criteria, with a history of hospitalization or the need for intravenous diuretic treatment in the previous 6 months, along with evidence of diastolic dysfunction based on echocardiographic criteria
  • Patients with or without Type II Diabetes Mellitus
  • Clinically stable condition (> 1 month after hospitalization for HF decompensation or since the last dose of intravenous diuretic treatment)
  • Clinical indication for cardiac catheterization
  • Clinical indication to receive de novo treatment with SGLT2 inhibitors
  • Signed informed consent

Who cannot take part

  • Participation in another clinical trial within 30 days prior to the start of the current study
  • Prior or current treatment with SGLT2 inhibitors
  • Stroke within 12 months prior to inclusion
  • Significant coronary artery disease
  • Aortic or mitral valvular disease ≥ moderate
  • Respiratory impairment or the need for home oxygen therapy
  • Contraindications for dapagliflozin treatment according to the product label (hereditary galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption; moderate-to-severe renal insufficiency - CrCl < 60 ml/min or eGFR < 60 ml/min/1.73 m² -; severe hepatic insufficiency)
  • Pregnant or breastfeeding women
  • Life expectancy of less than 2 years due to any cause

Where in Spain

  • Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting

About the trial

What the trial wants to find out

To identify the underlying the biological and biomechanical mechanisms responsible for the cardiovascular benefit demonstrated by iSGLT2 in patients with ICFEP.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Effects of sodium-glucose cotransporter 2 inhibition on the mechanisms of heart failure with preserved ejection fraction
Plain-language title
Studying how an SGLT2 inhibitor works in heart failure with preserved ejection fractionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
31 January 2025